Ozanimod

Research use only, not for human use.

Ozanimod (RPC-1063)is a potent, selective agonist of S1P1 and S1P5 receptor with EC50 of 0.41 nM and 11 nM respectively.

Ozanimod (RPC-1063)is a potent, selective agonist of S1P1 and S1P5 receptor with EC50 of 0.41 nM and 11 nM respectively; less potent for S1P2, S1P3 and S1P4 (EC50> 10 uM); induces S1P1 receptor internalization and induced a reversible reduction in circulating B and CCR7(+) T lymphocytes in vivo; shows high oral bioavailability and volume of distribution, and a circulatory half-life.Multiple Sclerosis Phase 3 Clinical

RPC-1063;RPC1063

GPCR/G Protein

Lysophospholipid Receptor

S1P1;S1P5

Inflammation/Immunology

Multiple Sclerosis

1306760-87-1

404.46

C23H24N4O3

>98% (HPLC)

DMSO: ≥ 29 mg/mL

N#CC1=CC(C2=NC(C3=CC=CC4=C3CC[C@@H]4NCCO)=NO2)=CC=C1OC(C)C

Benzonitrile, 5-[3-[(1S)-2,3-dihydro-1-[(2-hydroxyethyl)amino]-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)-

(-20℃)

With Ice Pack

≥ 2 years